

ATTORNEY'S DOCKET NUMBER
11413-003001**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**U.S. APPLICATION NO. (If Known, see 37 CFR
1.5) **09/744641**INTERNATIONAL APPLICATION NO.
PCT/EP99/05405INTERNATIONAL FILING DATE
28 July 1999PRIORITY DATE CLAIMED
29 July 1998TITLE OF INVENTION
NEW COFACTORS FOR METHYLTRANSFERASES

APPLICANT(S) FOR DO/EO/US

Marc Pignot and Elmar Weinhold

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

- ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
- ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
- ☒ This is an express request to promptly begin national examination procedures (35 U.S.C. 371(f)).
- ☒ The US has been elected by the expiration of 19 months from the priority date (PCT Article 31).
- ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
- a. ☒ is attached hereto (required only if not communicated by the International Bureau).
- b. ☐ has been communicated by the International Bureau.
- c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
- ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
- ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
- a. ☐ are attached hereto (required only if not communicated by the International Bureau).
- b. ☐ have been communicated by the International Bureau.
- c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
- d. ☒ have not been made and will not be made.
- ☐ An English language translation of amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
- ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
- ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 16 below concern other documents or information included:


- ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
- ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
- ☐ A FIRST preliminary amendment.
- ☐ A SECOND or SUBSEQUENT preliminary amendment.
- ☐ A substitute specification.
- ☐ A change of power of attorney and/or address letter.
- ☐ Other items or information:


☐
☐
☐
☐
☐
☐

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No. **EL688321763US**

I hereby certify under 37 CFR §1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

January 26, 2001
Date of Deposit

Gil Vargas
Typed Name of
Person Signing

S. APPL. NO. IF KNOWN 097744641		INTERNATIONAL APPLICATION NO. PCT/EP99/05405		ATTORNEY'S DOCKET NUMBER 11413-003001	
7. <input checked="" type="checkbox"/> The following fees are submitted:				CALCULATIONS PTO USE ONLY	
Basic National Fee (37 CFR 1.492(a)(1)-(5)):					
either international preliminary examination fee (37 CFR 1.482)					
or international search fee (37 CFR 1.445(a)(2)) paid to USPTO					
and International Search Report not prepared by the EPO or JPO.....				\$1000	
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO				\$860	
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International search fee (37 CFR 1.445(a)(2)) paid to USPTO.....				\$710	
International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4).....				\$690	
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4)				\$100	
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$860.00	
Surcharge of \$130 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$0.00	
Claims	Number Filed	Number Extra	Rate		
Total Claims	- 20 =		x \$18	\$0.00	
Independent Claims	- 3 =		x \$80	\$0.00	
MULTIPLE DEPENDENT CLAIMS(S) (if applicable)			+ \$270	\$0.00	
TOTAL OF ABOVE CALCULATIONS =				\$860.00	
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$430.00	
SUBTOTAL =				\$430.00	
Processing fee of \$130 for furnishing the English Translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f))				\$0.00	
TOTAL NATIONAL FEE =				\$430.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$0.00	
TOTAL FEES ENCLOSED =				\$430.00	
				Amount to be refunded:	\$
				Charged:	\$
a. <input checked="" type="checkbox"/> A check in the amount of \$430.00 to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. 06-1050 in the amount of \$0.00 to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 06-1050. A duplicate copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO:					
Gregory P. Einhorn FISH & RICHARDSON P.C. 4350 La Jolla Village Drive, Suite 500 San Diego, CA 92122 (858) 678-5070 phone (858) 678-5099 facsimile			 SIGNATURE : NAME Gregory P. Einhorn REGISTRATION NUMBER 38,440		

12

<213> Artificial Sequence

<223> synthetically generated oligonucleotide

<223> methylated cytosine

13

#8

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Marc Pignot et al.
Serial No. : 09/744,641
Filed : January 26, 2001
Title : NEW COFACTORS FOR METHYLTRANSFERASES

BOX PCT

Commissioner for Patents
Washington, D.C. 20231

RESPONSE TO NOTIFICATION TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE AND/OR AMINO ACID SEQUENCES

In response to the communication dated February 22, 2001, which was delivered to Fish & Richardson P.C. at the below referenced address on August 21, 2001 (copy enclosed), applicants submit herewith a Sequence Listing in computer readable form as required by 37 CFR §1.824. In addition, applicants submit an initial Sequence Listing as required under 37 CFR §1.823(a) and a statement under 37 CFR §1.821(f).

Applicants respectfully request entry of the paper copy and computer readable copy of the Sequence Listing filed herewith for the instant application. Furthermore, applicants request entry of the following amendments.

In the specification:

Insert the paper copy of the Sequence Listing filed herewith following the Oath/Declaration.

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No. EL584812217US

I hereby certify under 37 CFR §1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Date of Deposit 10/22/01

Signature Michael Augustine

Typed or Printed Name of Person Signing Certificate

Replace the paragraph beginning at page 9, line 1, with the following rewritten paragraph:

--In Reaction Scheme 4, lower, the modification of a short duplex oligodeoxynucleotide (3•4), consisting of a plus strand oligodeoxynucleotide (5'-GCCGCTCGATGCCG-3', 3; SEQ ID NO:1) and a complementary minus strand oligodeoxynucleotide (5'-CGGCATCGA^{Me}GCGGC-3', 4; SEQ ID NO:2) with the protonated cofactor analogue 2 containing aziridine by the use of the adenine-specific DNA methyltransferase from *Thermus aquaticus* (M•TaqI) is shown. The complementary minus strand oligodeoxynucleotide 4 was chosen to contain N6-methyladenine-1-β-D-2'-deoxynucleoside (A^{Me}), which can not be further methylated by M•TaqI. M•TaqI usually catalyzes methyl group transfer from the natural cofactor 1 to the exocyclic amino group of adenine within the double-stranded 5'-TCGA-3' DNA sequence (Scheme 4, upper) (M. McClelland, *Nucleic Acids Res.* 1981, 9, 6795-6804).--

Replace the paragraph beginning at page 11, line 17, with the following rewritten paragraph:

--The present invention, however, is not restricted to M•TaqI but the C5-cytosine-specific DNA methyltransferase *Haemophilus haemolyticus* (M•HhaI) and other methyltransferases normally using S-adenosyl-L-methionine (SAM) as cofactor can also be used. This is readily demonstrated by the modification of the duplex oligodeoxynucleotide 6•7 using M•HhaI (the sense and antisense strands depicted in Scheme 5 are SEQ ID NOs:3 and 4, respectively). Naturally, M•HhaI catalyzes the transfer of the activated methyl from SAM to the carbon atom at the 5 position of the first cytosine within the double stranded 5'-GCGC-3' DNA sequence (Scheme 5, upper). Experimental results prove that M•HhaI also accepts the new cofactor 2 and catalyzes its coupling to the duplex oligodeoxynucleotide 6•7 (Scheme 5, lower). Like the M•TaqI-catalyzed reaction, the M•HhaI-catalyzed coupling is quantitative.--

Replace the paragraph beginning at page 11, line 17, with the following rewritten paragraph:

--The M•*Taq*I-catalyzed coupling of the new fluorescent cofactor 9 with the duplex oligodeoxynucleotide 3•4 (Scheme 7; sense and antisense strands are SEQ ID NOs:1 and 2, respectively) was followed by anion exchange chromatography. After proteolytic fragmentation of the formed M•*Taq*I-DNA complex the fluorescently labeled duplex oligodeoxynucleotide 14•4 is formed. The structure of the product 14•4 was verified by enzymatic fragmentation followed by reversed-phase HPLC. The analysis revealed besides the natural nucleosides dC, dA, dG, T, and dA^{Me} an additional fluorescent compound, which eluted with a much higher retention time than the natural nucleosides demonstrating its hydrophobic nature. This additional fluorescent compound was isolated and detected as positively charged ion at *m/z* 863.1 by electrospray ionization mass spectrometry. The observed mass is in good agreement with the calculated molecular mass of 863.4 for a protonated, with 9 modified 2'-deoxyadenosine. Thus, the coupling reaction of the new fluorescent cofactor 9 with DNA catalyzed by M•*Taq*I is quantitative and base-specific.--

REMARKS

Applicants hereby submit that the enclosures fulfill the requirements under 37 C.F.R. §1.821-1.825. The amendments in the specification merely insert the paper copy of the Sequence Listing and sequence identifiers in the specification. No new matter has been added.

Attached hereto is a marked-up version of the changes made to the specification by the current amendment.

Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date:

Gregory P. Einhorn
Reg. No. 38,440

Fish & Richardson P.C.
4350 La Jolla Village Drive, Suite 500
San Diego, CA 92122
Telephone: (858) 678-5070
Facsimile: (858) 678-5099

“Version With Markings to Show Changes Made”

In the specification:

Paragraph beginning at page 9, line 1, has been amended as follows:

In Reaction Scheme 4, lower, the modification of a short duplex oligodeoxynucleotide (3•4), consisting of a plus strand oligodeoxynucleotide (5'-GCCGCTCGATGCCG-3', 3; SEQ ID NO:1) and a complementary minus strand oligodeoxynucleotide (5'-CGGCATCGA^{Me}GCGGC-3', 4; SEQ ID NO:2) with the protonated cofactor analogue 2 containing aziridine by the use of the adenine-specific DNA methyltransferase from *Thermus aquaticus* (M•TaqI) is shown. The complementary minus strand oligodeoxynucleotide 4 was chosen to contain N6-methyladenine-1-β-D-2'-deoxynucleoside (A^{Me}), which can not be further methylated by M•TaqI. M•TaqI usually catalyzes methyl group transfer from the natural cofactor 1 to the exocyclic amino group of adenine within the double-stranded 5'-TCGA-3' DNA sequence (Scheme 4, upper) (M. McClelland, *Nucleic Acids Res.* 1981, 9, 6795-6804).

Paragraph beginning at page 11, line 17, has been amended as follows:

The present invention, however, is not restricted to M•TaqI but the C5-cytosine-specific DNA methyltransferase *Haemophilus haemolyticus* (M•HhaI) and other methyltransferases normally using S-adenosyl-L-methionine (SAM) as cofactor can also be used. This is readily demonstrated by the modification of the duplex oligodeoxynucleotide 6•7 using M•HhaI (the sense and antisense strands depicted in Scheme 5 are SEQ ID NOs:3 and 4, respectively). Naturally, M•HhaI catalyzes the transfer of the activated methyl from SAM to the carbon atom at the 5 position of the first cytosine within the double stranded 5'-GCGC-3' DNA sequence (Scheme 5, upper). Experimental results prove that M•HhaI also accepts the new cofactor 2 and catalyzes its coupling to the duplex oligodeoxynucleotide 6•7 (Scheme 5, lower). Like the M•TaqI-catalyzed reaction, the M•HhaI-catalyzed coupling is quantitative.

Paragraph beginning at page 11, line 17, has been amended as follows:

The M•*TaqI*-catalyzed coupling of the new fluorescent cofactor 9 with the duplex oligodeoxynucleotide 3•4 (Scheme 7; sense and antisense strands are SEQ ID NOs:1 and 2, respectively) was followed by anion exchange chromatography. After proteolytic fragmentation of the formed M•*TaqI*-DNA complex the fluorescently labeled duplex oligodeoxynucleotide 14•4 is formed. The structure of the product 14•4 was verified by enzymatic fragmentation followed by reversed-phase HPLC. The analysis revealed besides the natural nucleosides dC, dA, dG, T, and dA^{Me} an additional fluorescent compound, which eluted with a much higher retention time than the natural nucleosides demonstrating its hydrophobic nature. This additional fluorescent compound was isolated and detected as positively charged ion at m/z 863.1 by electrospray ionization mass spectrometry. The observed mass is in good agreement with the calculated molecular mass of 863.4 for a protonated, with 9 modified 2'-deoxyadenosine. Thus, the coupling reaction of the new fluorescent cofactor 9 with DNA catalyzed by M•*TaqI* is quantitative and base-specific.

11413-003001

PTO/PCT Rec'd 22 OCT 2001

Patent's Docket No.: 11413-003001 / B 2286 US

#8

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Marc Pignot et al.
Serial No. : 09/744,641
Filed : January 26, 2001
Title : NEW COFACTORS FOR METHYLTRANSFERASES

BOX PCT

Commissioner for Patents
Washington, D.C. 20231

VERIFIED STATEMENT UNDER 37 CFR §1.821(f)

I, Jennifer H. Payne, declare that I personally prepared the paper and the computer-readable copy of the Sequence Listing filed herewith for the above-identified application and that the content of both is the same.

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of The United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date: October 19, 2001

Jennifer H. Payne
Jennifer H. Payne

Fish & Richardson P.C.
225 Franklin Street
Boston, Massachusetts 02110-2804
(617) 542-5070 telephone
(617) 542-8906 facsimile

20311474.doc

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No. E258481221745

I hereby certify under 37 CFR §1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Date of Deposit 10/22/01
Michael Augustine
Signature

Michael Augustine
Typed or Printed Name of Person Signing Certificate

New cofactors for methyltransferases

The present invention refers to aziridine derivatives which can be used as cofactors for methyltransferases, complexes and compositions containing these compounds and their use for modifying a target molecule.

Nonradioactively labeled nucleic acids are of considerable interest in molecular biology, because they can be used in DNA sequencing and can serve as probes for Southern/Northern blots, *in situ* hybridizations and colony/plaque screenings without the potential health hazards of radioactive material. Several methods are presently known in the art of covalently modifying DNA and RNA (reviewed by C. Kessler in *Nonisotopic DNA Probe Techniques*, L. J. Kricka (Ed.), Academic Press, San Diego, 1992, pp. 29-92). For instance, modified oligonucleotides can be obtained by solid-phase DNA or RNA synthesis and the so modified oligodeoxynucleotides can be used as primers for a DNA polymerase (P. Richterich, G. M. Church, *Methods Enzym.* 1993, 218, 187-222). If the modification can not withstand the reaction conditions used in the solid-phase synthesis, incorporation of amine or thiol groups and postsynthetic labeling of the obtained oligonucleotides with amine or thiol reactive probes is possible (D. M. Jameson, W. H. Sawyer, *Methods Enzym.* 1995, 246, 283-300). In addition, several labels may be coupled to terminal phosphate or thiophosphate residues in oligonucleotides (J.-L. Mergny et al., *Nucleic Acids Res.* 1994, 22, 920-928).

Another method described in the art is the incorporation of modified deoxynucleosidetriphosphates into DNA with DNA polymerases (A. Waggoner, *Methods Enzym.* 1995, 246, 362-373) or with terminal deoxynucleotidyl transferase (L. K. Riley, M. E. Marshall, M. S. Coleman, *DNA* 1986, 5, 333-338; G. L. Trainor, M. A. Jensen, *Nucleic Acids Res.* 1988, 16, 11846).

Furthermore, several modifications may be incorporated directly in DNA or RNA. For example, cytosine residues can be modified by activation with bisulfite followed by coupling with aliphatic amines (R. P. Viscidi, *Methods Enzym.* 1990, 184, 600-607; D. E. Draper, L. Gold, *Biochemistry* 1980, 19, 1774-1781). In addition, other chemical reagents for labeling DNA and RNA are commercially available (FastTag, Vector, Burlingame, CA; Mirus Label IT, Pan Vera Corporation,

Madison, WI). These later methods, however, do not result in quantitative and sequence specific modifications and thus complex mixtures are obtained.


Nonradioactive labeling of proteins is straightforward, because their cysteine and lysine residues react readily with a large variety of labeling reagents (M. Brinkley, *Bioconjugate Chem.* 1992, 3, 2-13; R. P. Haugland, *Handbook of Fluorescent Probes and Research Chemicals* 1996, Molecular Probes Inc., Eugene, OR). However, generally proteins contain many lysine or cysteine residues and labeling often results in complex mixtures which are difficult to analyze. Thus, the specific modification of proteins is even more difficult than that of DNA and RNA. One strategy to obtain specifically labeled proteins is to engineer a protein with a single cysteine residue by means of a mutagenesis; subsequently, this cysteine residue is modified for example with a fluorescent group (G. Haran, E. Haas, B. K. Szpikowska, M. T. Mas, *Proc. Natl. Acad. Sci. USA* 1992, 89, 11764-11768).

Furthermore, unnatural amino acids may be incorporated into proteins by *in vitro* translation (V. W. Cornish, D. Mendel, P. G. Schultz, *Angew. Chem.* 1995, 107, 677-690; *Angew. Chem. Int. Ed. Engl.* 1995, 34, 620-630). However, this method cannot easily be carried out and it results in only a small amount of modified protein.

Another possibility is the preparation of modified proteins by chemical peptide synthesis (T. W. Muir, S. B. H. Kent, *Current Opinion in Biotechnology* 1993, 4, 420-427); however, it is generally restricted to the preparation of relatively short protein chains.

It is the object of the present application to overcome the drawbacks of the known methods and to provide novel compounds which enable modification of biomolecules (for instance labeling) in a simple and effective way by the use of a methyltransferase.

This object is achieved by aziridine derivatives represented by formula (I)



wherein X is N or CH, Y is N or $-\text{CR}^3$, R^1 and R^3 independently from each other are H, ^3H , $-\text{NH}(\text{CH}_2)_n\text{NHR}^4$ or $-\text{NH}(\text{C}_2\text{H}_5\text{O})_n\text{C}_2\text{H}_5\text{NHR}^4$, with R^4 being selected from fluorophores, affinity tags, crosslinking agents, chromophors, proteins, peptides, amino acids which may optionally be modified, nucleotides, nucleosides, nucleic acids, carbohydrates, lipids, PEG, transfection reagents, beads and intercalating agents and n being an integer from 1-5000, and R^2 is selected from H, ^3H , $-\text{N}(\text{CH}_2)_n\text{NHR}^4$, $-\text{NH}(\text{C}_2\text{H}_5\text{O})_n\text{C}_2\text{H}_5\text{NHR}^4$ wherein R^4 and n are as defined above, $-\text{CH}_2\text{CH}(\text{COOH})(\text{NH}_2)$ or an electron-withdrawing group.

Figure 1 shows the anion exchange chromatography of the enzyme reaction with *M·TaqI* of Example 1 after different incubation times.

Figure 2A shows the RP-HPLC/ESI mass spectrum of the product duplex oligodeoxynucleotide 5-4 of Example 1 eluted after 14.6 min.

Figure 2B shows the ESI mass spectrum of the product 5-4 of Example 1 obtained by direct infusion.

Figure 3 shows the anion exchange chromatography of the enzyme reaction with *M·HhaI* of Example 1 after different incubation times.

Figure 4 shows the RP-HPLC/ESI mass spectrum of the product duplex oligodeoxynucleotide 8-7 of Example 1.

Figure 5 shows the anion exchange chromatography (UV- and fluorescence detection) of the enzyme reaction with *M·TaqI* of Example 2.

Figure 6 shows the chromatogram of labeled plasmid DNA (Example 2, labeling 3.1 with *M·TaqI*) of the anion exchange chromatography after different incubation times (6A: UV detection at 260 nm; 6B: fluorescence detection).

Figure 7 shows the chromatograms (7A: UV detection at 260 nm; 7B: fluorescence detection) obtained for non-labeled pUC19 (Example 2, labeling 3.1 without *M·TaqI*) for comparison reasons.


Figure 8 shows the chromatograms (8A: UV detection at 260 nm; 8B: fluorescence detection) of labeled and non-labeled pUC19 (Example 2, labeling 3.2 with and without *M·HhaI*);

The present invention will now be described in more detail.

S-Adenosyl-L-methionine-dependent methyltransferases (SAM-dependent methyltransferases) are a biologically important class of enzymes. They represent about 3% of the enzymes listed in the latest version of *Enzyme Nomenclature*, E. C. Webb, Academic Press, San Diego, 1992. They catalyze the transfer of the activated methyl group from the cofactor S-adenosyl-L-methionine to sulfur, nitrogen, oxygen and carbon nucleophiles of small molecules, phospholipids, proteins, RNA and DNA. For instance, DNA methyltransferases catalyze the methylation of the N6 position of adenine and the C5 or N4 position of cytosine within specific DNA sequences. Since restriction endonucleases are sensitive to DNA methylation, DNA methyltransferases can be used to decrease the number of restriction sites in DNA (M. Nelson, I. Schildkraut, *Methods Enzymol.* 1987, 155, 41-48).


The reaction known to be catalyzed by SAM-dependent methyltransferases is shown schematically in the Reaction Scheme 1, where compound 1 is the cofactor S-adenosyl-L-methionine (SAM).

Reaction Scheme 1



The inventors of the present application have now found that the aziridine derivatives of Formula I below serve as cofactors for SAM-dependent methyltransferases and by this way enable the transfer of groups larger than methyl.

The aziridine derivatives of the present invention are represented by Formula (I)



wherein X is N or CH, Y is N or -CR³, R¹ and R³ independently from each other are H, ³H, -NH(CH₂)_nNHR⁴ or -NH(C₂H₅O)_nC₂H₅NHR⁴, with R⁴ being selected from fluorophores, affinity tags, crosslinking agents, chromophors, proteins, peptides, amino acids which may optionally be modified, nucleotides, nucleosides, nucleic acids, carbohydrates, lipids, PEG, transfection reagents, beads and intercalating agents and n being an integer from 1-5000, and R² is selected from H, ³H, -N(CH₂)_nNHR⁴, -NH(C₂H₅O)_nC₂H₅NHR⁴ wherein R⁴ and n are as defined above, -CH₂CH(COOH)(NH₂) or an electron-withdrawing group.

Preferred electron-withdrawing groups are -CH_{3-p}R⁵_p (wherein p=1, 2 or 3 and each R⁵ is independently selected from fluorine, chlorine, bromine and iodine, preferably fluorine and chlorine), -C≡N and -C(O)R⁶ (wherein R⁶ is an alkoxy group, hydroxy or an amino group which may be mono- or di-substituted with C₁-C₁₀ alkyl or C₆-C₁₀ aryl).

It is preferred that only one of R¹, R² and R³ is -NH(CH₂)_nNHR⁴ or -NH(C₂H₅O)_nC₂H₅NHR⁴. In preferred compounds X and/or Y is N; especially preferred are compounds wherein X and Y both are N.

In the group -NH(CH₂)_nNHR⁴ n preferably is an integer from 2 to 20, especially preferred n = 3, 4 or 5.

In the group -NH(C₂H₅O)_nC₂H₅NHR⁴ n preferably is an integer from 1 to 250; more preferred n is an integer from 1 to 20.

The term fluorophore as used herein is a chemical entity in which the electrons can be excited with light of a certain energy and photons with lower energy are emitted afterwards.

In preferred compounds of the present invention R^1 and R^2 are each H or ^3H and X is N.


If at least one of R^1 , R^2 and R^3 is $-\text{NH}(\text{CH}_2)_n\text{NHR}^4$ or $-\text{NH}(\text{C}_2\text{H}_5\text{O})_n\text{C}_2\text{H}_5\text{NHR}^4$, R^4 is selected from fluorophores, affinity tags, cross-linking agents, chromophores, proteins (including antibodies and enzymes), peptides, amino acids, modified amino acids, nucleotides, nucleosides, nucleic acids, carbohydrates, lipids, PEG, transfection reagents (including polyethyleneimine, macromolecules, dendrimers), beads (e.g. those consisting of agarose, silica, nitrocellulose, cellulose, acrylamide, latex, polystyrene, polyacrylate, polymethacrylate, polyethylene polymers, glass particles, silicates, metal oxides or combinations thereof), intercalating agents (including ethidium bromide, psoralene and derivatives thereof). Preferred fluorophores are BODIPY, coumarin, dansyl, fluorescein, mansyl, pyrene, rhodamine, Texas red, TNS and cyanine fluorophores like Cy2, Cy3, Cy3.5, Cy5, Cy5.5 and Cy7; derivatives of these fluorophores can also be used. An especially preferred value for R^4 is dansyl.

If R^4 is an affinity tag, it is preferably a peptide tag, biotin, digoxigenin or dinitrophenol; useful peptide tags are for example his-tag- or any tag with metal chelating properties which can be used in IMAC (Immobilized Metal Affinity Chromatography), strep-tag, flag-tag, c-myc-tag, epitopes, or glutathione.

Useful crosslinking agents are for example maleimide, iodacetamide, derivatives thereof, aldehyde derivatives and photocrosslinking agents. Examples for photocrosslinking agents are arylazide, diazo-compounds and benzophenone compounds.


N-Adenosylaziridine (compound 2) can for instance be synthesized in a one-step reaction by nucleophilic substitution of the tosylate group of 5'-tosyladenosine with aziridine (see Reaction Scheme 2 below).

Reaction Scheme 2



Reaction Scheme 3 shows the reaction catalyzed by a methyltransferase (MTase) using the natural cofactor 1 and on the other hand using the new cofactor 2 according to the present invention.


Reaction Scheme 3



In Reaction Scheme 4, lower, the modification of a short duplex oligodeoxynucleotide (3-4), consisting of a plus strand oligodeoxynucleotide (5'-GCCGCTCGATGCCG-3', 3) and a complementary minus strand oligodeoxynucleotide (5'-CGGCATCGA^{Me}GCGGC-3', 4) with the protonated cofactor analogue 2 containing aziridine by the use of the adenine-specific DNA methyltransferase from *Thermus aquaticus* (M·TaqI) is shown. The complementary minus strand oligodeoxynucleotide 4 was chosen to contain N6-methyladenine-1-β-D-2'-deoxynucleoside (A^{Me}), which can not be further methylated by M·TaqI. M·TaqI usually catalyzes the methyl group transfer from the natural cofactor 1 to the exocyclic amino group of adenine within the double-stranded 5'-TCGA-3' DNA sequence (Scheme 4, upper) (M. McClelland, *Nucleic Acids Res.* 1981, 9, 6795-6804).

The structure of the reaction product 5·4 can for instance be verified by reversed phase HPLC-coupled electrospray ionization mass spectrometry (RP-HPLC/ESI-MS).


Reaction Scheme 4



Experimental results prove that with the unnatural cofactor 2 the non-methylated plus strand 3, which contains an adenine at the target position within the 5'-TCGA-3' recognition sequence of M·*TaqI*, is modified quantitatively. Our observation that strand 4, which contains N6-methyladenine at the other target position and an adenine outside the recognition sequence, is not modified, demonstrates that the sequence specificity of M·*TaqI* is not altered with the new cofactor 2. In addition, enzymatic fragmentation of the product duplex 5·4 followed by reversed-phase HPLC analysis yielded an additional compound besides the natural nucleosides dC, dA, dG, T, and dA^{Me}. This additional compound was isolated and detected as positively charged ion at m/z 544.6 by electrospray ionization mass spectrometry. The observed mass is identical with the calculated molecular mass of a protonated, with N-adenosylaziridine modified 2'-deoxyadenosine. This result demonstrates that only the target adenine in the plus strand 3 is modified. Thus, the M·*TaqI*-catalyzed coupling of the new cofactor 2 with DNA is quantitative, sequence- and base-specific.

The present invention, however, is not restricted to M·*TaqI* but the C5-cytosine-specific DNA methyltransferase *Haemophilus haemolyticus* (M·*HhaI*) and other methyltransferases normally using S-adenosyl-L-methionine (SAM) as cofactor can also be used. This is readily demonstrated by the modification of the duplex oligodeoxynucleotide 6·7 using M·*HhaI*. Naturally, M·*HhaI* catalyzes the transfer of the activated methyl from SAM to the carbon atom at the 5 position of the first cytosine within the double stranded 5'-GCGC-3' DNA sequence (Scheme 5, upper). Experimental results prove that M·*HhaI* also accepts the new cofactor 2 and catalyzes its coupling to the duplex oligodeoxynucleotide 6·7 (Scheme 5, lower). Like the M·*TaqI*-catalyzed reaction, the M·*HhaI*-catalyzed coupling is quantitative.


Reaction Scheme 5




This application for the first time describes the transfer of a group larger than a methyl group catalyzed by two different S-adenosyl-L-methionine-dependent methyltransferase. Since the transfer of for instance compound 2 introduces a unique secondary amino group into DNA, subsequent labeling reactions with amine reactive probes should be feasible. Thus, site-specific introduction of fluorescent, chemiluminescent or other reporter groups is possible.

Alternatively, the new fluorescent cofactor 9 where R^1 is $-\text{NH}(\text{CH}_2)_4\text{NHR}^4$, R^2 is H, Y is N and R^4 is the fluorescent dansyl group can be used to obtain sequence-specifically labeled DNA directly. This fluorescent N-adenosylaziridine derivative contains the reactive aziridine group at the 5' position, the adenosyl moiety, which serves as the molecular anchor for the cofactor binding of methyltransferases, and the fluorescent dansyl group (label), which is attached to the 8 position via a flexible linker. The synthesis of this new fluorescent cofactor 9 is illustrated in Scheme 6. Reaction of 8-bromo-2',3'-O-isopropylidene adenosine with 1,4-diaminobutane yields the protected adenosine derivative 10 with an aminolinker at the 8 position. Transient protection of the 5' hydroxy group with trimethylchlorosilan, coupling of dansyl chloride with the primary amine and removal of the 5' hydroxyl protecting group leads to the protected fluorescent adenosine derivative 11. Reaction of 11 with mesylchloride yields the mesylate 12. Removal of the isopropylidene group of 12 under acidic conditions leads to the fluorescent adenosine derivative 13 which is reacted with aziridine to give the new fluorescent cofactor 9.

Reaction Scheme 6



The M·*TaqI*-catalyzed coupling of the new fluorescent cofactor 9 with the duplex oligodeoxynucleotide 3·4 (Scheme 7) was followed by anion exchange chromatography. After proteolytic fragmentation of the formed M·*TaqI*–DNA complex the fluorescently labeled duplex oligodeoxynucleotide 14·4 is formed. The structure of the product 14·4 was verified by enzymatic fragmentation followed by reversed-phase HPLC. The analysis revealed besides the natural nucleosides dC, dA, dG, T, and dA^{Me} an additional fluorescent compound, which eluted with a much higher retention time than the natural nucleosides demonstrating its hydrophobic nature. This additional fluorescent compound was isolated and detected as positively charged ion at m/z 863.1 by electrospray ionization mass spectrometry. The observed mass is in good agreement with the calculated molecular mass of 863.4 for a protonated, with 9 modified 2'-deoxyadenosine. Thus, the coupling reaction of the new fluorescent cofactor 9 with DNA catalyzed by M·*TaqI* is quantitative and base-specific.



The present invention can also be used to label larger DNA molecules. This is proved by labeling of the plasmid pUC19 (2,686 base pairs) with the new fluorescent cofactor 9 and M·*TaqI*. The labeling reaction was analyzed by anion exchange chromatography after different incubation times. While the chromatograms using UV detection did not significantly change, the chromatograms using fluorescence detection clearly showed an increase of the fluorescence signal with the incubation time. The UV signal and the fluorescence signal superimpose and indicate that the starting material pUC19 (UV absorption only) and fluorescently labeled pUC19 (UV absorption and fluorescence) elute with the same retention time. In a parallel control experiment without M·*TaqI* no fluorescence signal corresponding to fluorescently labeled pUC19 was observed. This result demonstrates that the labeling reaction is in fact M·*TaqI*-catalyzed. Interestingly, the fluorescent nucleoside 9 also function as a cofactor for M·*HhaI*. Analysis of the M·*HhaI*-catalyzed coupling reaction between fluorescent nucleoside 9 and pUC19 by anion exchange chromatography shows that fluorescently labeled pUC19 is also produced and that no labeling occurs without M·*HhaI*.

The three-dimensional structures of several methyltransferases in complex with the natural cofactor (N6-adenine DNA methyltransferase M·*TaqI*: J. Labahn, J. Granzin, G. Schluckebier, D. P. Robinson, W. E. Jack, I. Schildkraut, W. Saenger, *Proc. Natl. Acad. Sci. USA* 1994, 91, 10957-10961; N6-adenine DNA methyltransferase DpnM: P. H. Tran, Z. R. Korszun, S. Cerritelli, S. S. Springhorn, S. A. Lacks, *Structure* 1998, 6, 1563-1575; C5-cytosine DNA methyltransferase M·*HhaI*: S. Klimasauskas, S. Kumar, R. J. Roberts, X. Cheng, *Cell* 1994, 76, 357-369; N4-cytosine DNA methyltransferase M·*PvuII*: W. Gong, M. O'Gara, R. M. Blumenthal, X. Cheng, *Nucleic Acids Res.* 1997, 25, 2702-2715; N6-adenine RNA methyltransferase ErmC': D. E. Bussiere, S. W. Muchmore, C. G. Dealwis, G. Schluckebier, V. L. Nienaber, R. P. Edalji, K. A. Walter, U. S. Lador, T. F. Holzman, C. Abad-Zapatero, *Biochemistry* 1998, 37, 7103-7112; mRNA 2'-O-nucleoside methyltransferase VP39: A. E. Hodel, P. D. Gershorn, X. Shi, F. A. Quioco, *Cell* 1996, 85, 247-256; protein methyltransferase CheR: S. Djordjevic, A. M. Stock, *Structure* 1997, 5, 545-558) indicate that the 8 position of the adenine ring of the natural cofactor is at least partly accessible to the solvent, and thus is suitable for the attachment of an additional group without strongly interfering with the cofactor binding of these methyltransferases. In some methyltransferases the 7 position of the adenine ring of the natural cofactor is even more exposed to the solvent and, therefore, might be the preferred position of choice for the attachment of additional groups (Y in Formula I) for these methyltransferases. In addition, the

three-dimensional structure of the catechol O-methyltransferase COMT in complex with the natural cofactor (J. Vidgren, L. A. Svensson, A. Liljas, *Nature* 1994, 368, 354-358) shows that the adenine ring of the natural cofactor is buried within the cofactor binding pocket. Here, the attachment of an additional group at the 5' aziridine ring (R^2 in Formula I) seems most compatible with the cofactor binding of this methyltransferase. Thus, the new cofactors with modifications at the 8-position of the adenine ring (R^1 in Formula I), at the 7 position of the adenine ring (Y in Formula I) or at the 5' aziridine ring (R^2 in Formula I) can be used to obtain a wide variety of site-specifically labeled biomolecules.

The methyltransferases useful in the present invention normally transfer the methyl group of SAM onto a nucleic acid molecule like DNA or RNA, onto a polypeptide, a protein, an enzyme or a small molecule. An overview on SAM-dependent methyltransferases is for instance given by R. M. Kagan and S. Clarke in *Archives of Biochemistry and Biophysics* 1994, 310, 417-427. This article also gives a list of small molecule O-methyltransferases and small molecule N-methyltransferases which include for example catechol O-methyltransferase and glycine N-methyltransferase.

Particularly preferred for use in the present invention are methyltransferases which methylate DNA, especially, those which are part of a restriction modification system of a bacterium and methyltransferases which methylate proteins at distinct amino acids.

The present invention not only refers to the aziridine derivatives themselves but also to the complex of such a derivative and a methyltransferase as well as pharmaceutical and diagnostic compositions comprising an aziridine derivative of the present invention or a complex thereof with a methyltransferase.

The aziridine derivatives of the present invention can be used for modifying a target molecule (e.g. DNA or fragments thereof, RNA or fragments thereof, hybrids of DNA and RNA, polypeptides, for instance proteins of fusion proteins comprising a methylation site, synthetic polymers and small molecules like lipids). This can be done by transferring an aziridine derivative of the present invention or a part thereof onto the target molecule by means of a methyltransferase.

The present invention will now be further illustrated by the following examples.

Example 1

1. Synthesis of N-adenosylaziridine, compound 2 (Scheme 2).

Dry aziridine (S. Gabriel, *Chem. Ber.* 1888, 21, 2664-2669; S. Gabriel, R. Stelzner, *Chem. Ber.* 1895, 28, 2929-2938) (360 μ l, 7.2 mmol) was added slowly to a suspension of 5'-tosyladenosine (100 mg, 0.24 mmol, Aldrich) in N-ethyldiisopropylamine (125 μ l, 0.7 mmol) under an argon atmosphere, and the resulting solution was stirred at room temperature for three days. Any aziridine remaining was removed under reduced pressure, and the crude reaction product was dissolved in water (1 ml) and neutralized with acetic acid (1 M). The solution (100 μ l at a time) was injected onto a reversed-phase HPLC column (Hypersil-ODS, 5 μ m, 120 Å, 250 x 10 mm, Bischoff, Leonberg, Germany), and the product was eluted with a linear gradient of acetonitrile (7–10% in 30 min, 2 ml/min) in triethylammonium hydrogencarbonate buffer (0.1 M, pH 8.4). Fractions containing product (retention time 11.3 min, UV detection at 259 nm) were combined, concentrated by lyophilization to 5.5 ml (10.5 mM, using $\lambda = 260$, $\epsilon = 15400$ of adenosine) and stored at -80°C . Yield: 0.058 mmol (24%). For further characterization an aliquot was completely lyophilized to afford compound 2 as a white solid.

^1H NMR (500 MHz, D_2O): $\delta = 1.49\text{--}1.40$ (m, 2H; aziridine-H), 1.85–1.74 (m, 2H; aziridine-H), 2.74 and 2.68 (AB part of ABX-spectrum, $^3J = 4.3, 6.6$ Hz, $^2J = 13.3$ Hz, 2H; 5'- H_a , 5'- H_b), 4.35 (ddd = dt, $^3J = 4.6, 4.6, 6.7$ Hz, 1H; 4'-H), 4.46 (dd = t, $^3J = 5.1$ Hz, 1H; 3'-H), 4.84 (dd = t, $^3J = 5.3$ Hz, 1H; 2'-H), 6.13 (d, $^3J = 5.0$ Hz, 1H; 1'-H), 8.30 (s, 1H; 8-H), 8.36 (s, 1H; 2-H).

FAB-MS (thioglycolic acid): m/z (%): 293 (100) [$M^+ + \text{H}$], 250 (4) [$M^+ - \text{C}_2\text{H}_4\text{N}$], 178 (11) [$\text{B}^+ + \text{C}_2\text{H}_4\text{O}$], 167 (34), 165 (5), 164 (5) [$\text{B}^+ + \text{CH}_2\text{O}$], 158 (36) [$M^+ - \text{B}$], 149 (78), 136 (91) [BH_2^+], 102 (23); B = deprotonated adenine.

2. Synthesis and purification of oligodeoxynucleotides.

Oligodeoxynucleotides 3, 4, 6 and 7 were synthesized on an Applied Biosystems 392 DNA/RNA synthesizer, using standard β -cyanoethyl phosphoramidite chemistry. Syntheses were performed "trityl on" and oligodeoxynucleotides were purified by reversed-phase HPLC. After

detritylation with acetic acid (80%), the oligodeoxynucleotides were further purified by reversed-phase HPLC ("trityl off") and desalted by gel filtration. The duplex oligodeoxynucleotides 3·4 and 6·7 were formed by incubating equal molar amounts of the complementary strands in buffer (20 mM Tris acetate, 50 mM potassium acetate, 10 mM magnesium acetate, pH 7.9 for 3·4 and 10 mM Tris chloride, 50 mM sodium chloride, 0.5 mM EDTA, pH 7.4 for 6·7) at 95°C (2 min) followed by slow cooling (2 h) to room temperature.

3. Enzyme reactions

3.1 Enzyme reaction with the N6-adenine DNA methyltransferase M·*TaqI*.

The DNA methyltransferase M·*TaqI* free of cofactor was prepared as described before (B. Holz, S. Klimasauskas, S. Serva, E. Weinhold, *Nucleic Acids Res.* 1998, 26, 1076-1083). The enzyme-catalyzed reaction was carried out in a mixture (500 µl) of M·*TaqI* (5 nmol, 10 µM), duplex oligodeoxynucleotide 3·4 (5 nmol, 10 µM), compound 2 (500 nmol, 1 mM), Tris acetate (20 mM, pH 6.0), potassium acetate (50 mM), magnesium acetate (10 mM) and Triton X-100 (0.01%) at 37°C. The progress of the reaction was monitored by anion exchange chromatography. Aliquots (50 µl) of the reaction mixture were withdrawn after different incubation times, mixed with an urea solution (100 µl, 6 M) and injected onto an anion exchange column (Poros 10 HQ, 10 µm, 4.6 x 100 mm, PerSeptive Biosystems, Germany). Compounds were eluted with aqueous potassium chloride (0.5 M for 5 min, followed by a linear gradient to 1 M in 30 min, 4 ml/min) in Tris chloride buffer (10 mM, pH 7.6). The chromatograms of the anion exchange chromatography after different incubation times are shown in Figure 1.

Analysis of the product duplex oligodeoxynucleotide 5·4 by reversed-phase HPLC-coupled electrospray ionization mass spectrometry: RP-HPLC/ESI-MS was performed with an ion-trap mass spectrometer (LCQ, Finnigan MAT, Germany) equipped with a micro HPLC system (M480 and M300, GynkoteK, Germany). The product duplex oligodeoxynucleotide 5·4 was purified by anion exchange chromatography (see above) and desalted by repeated addition of water and ultrafiltration (Microsep 3K, Pall Filtron, Northborough, MA, USA). A solution of purified and desalted 5·4 was injected onto a capillary column (Hypersil-ODS, 3 µm, 150 x 0.3 mm, LC Packings, Amsterdam, Netherlands) and eluted with a linear gradient of acetonitrile (7–

10% in 10 min, followed by 10–70% in 30 min, 150 μ l/min) in triethylammonium acetate buffer (0.1 M, pH 7.0). The RP-HPLC/ESI mass spectra shown in Figure 2A was obtained in the negative ion mode using standard conditions. The chromatogram obtained by observing the total ion current is given in the inset of Figure 2A.

Analysis of the product duplex oligodeoxynucleotide 5-4 by electrospray ionization mass spectrometry using direct infusion: The ESI mass spectrum shown in Figure 2B was acquired using a double focussing sector field mass spectrometer MAT 90 (Finnigan MAT, Germany) equipped with an ESI II electrospray ion source in the negative ion mode. Desalted 5-4 (aqueous solution) and a liquid sheath flow (2-propanol) were delivered using a Harvard syringe pump (Harvard Apparatus, USA). The inset in Figure 2B shows an expansion of the signal for the $[5-6H]^{6-}$ ion with isotopic resolution.

The molecular weights of oligodeoxynucleotides observed in the electrospray mass spectra from Figure 2A and 2B are summarized in Table 1. In addition, the observed molecular weights of the educt oligodeoxynucleotides are given.

Table 1

Compound	Charge	$(m/z)_{\text{expt}}$	M_{expt}	M_{calcd}
1) RP-HPLC/ESI-MS				
5-4	5 –	1766.5	8837.5	8836.9
5	3 –	1510.1	4533.3	4533.1
4	3 –	1433.9	4304.7	4303.8
3-4	5 –	1708.0	8545.0	8544.6
3	3 –	1412.7	4241.1	4240.8
2) ESI-MS by direct infusion				
5	6 –	754.5	4533.1	4533.1
4	6 –	716.1	4302.7	4303.8
3	6 –	705.7	4240.3	4240.8

Analysis of the product duplex oligodeoxynucleotide 5-4 by enzymatic fragmentation: Purified and desalted 5-4 (0.25 OD at 260 nm) was dissolved in potassium phosphate buffer (10 mM, pH 7.0, 100 μ l) containing magnesium chloride (10 mM), DNase I (1.2 U), phosphodiesterase from

Crotalus durissus (0.018 U), phosphodiesterase from calf spleen (0.024 U) and alkaline phosphatase (6 U) and incubated at 37°C for 24 h. An aliquot (50 µl) was injected onto a reversed-phase HPLC column (Hypersil-ODS, 5 µm, 120 Å, 250 x 4.6 mm, Bischoff, Leonberg, Germany), and the products were eluted with a linear gradient of acetonitrile (0–10.5% in 30 min, 1 ml/min) in triethylammonium acetate buffer (0.1 M, pH 7.0). The RP-HPLC analysis of the digest revealed besides dC, dA, dG, T, and dA^{Me} an additional compound eluting between T and dA^{Me}. This additional compound was isolated and detected as positively charged ion at m/z 544.6 by ESI-MS (LCQ connected to a nanoelectrospray ion source, Finnigan MAT, Germany). The observed mass is identical with the calculated molecular mass of a protonated, with N-adenosylaziridine modified 2'-deoxyadenosine.

3.2 Enzyme reaction with the C5-cytosine DNA methyltransferase M·HhaI.

The DNA methyltransferase M·HhaI free of cofactor was prepared as described before (B. Holz, S. Klimasauskas, S. Serva, E. Weinhold, *Nucleic Acids Res.* 1998, 26, 1076-1083). The enzyme-catalyzed reaction was carried out in a mixture (500 µl) of M·HhaI (5 nmol, 10 µM), duplex oligodeoxynucleotide 6·7 (5 nmol, 10 µM), compound 2 (500 nmol, 1 mM), Tris chloride (10 mM, pH 7.4), sodium chloride (50 mM), EDTA (0.5 mM) and Triton X-100 (0.01%) at 25°C. The progress of the reaction was monitored by anion exchange chromatography. Aliquots (50 µl) of the reaction mixture were withdrawn after different incubation times, and injected onto an anion exchange column (Poros 10 HQ, 10 µm, 4.6 x 100 mm, PerSeptive Biosystems, Germany). Compounds were eluted with aqueous potassium chloride (0 M for 5 min, followed by a linear gradient to 0.5 M in 5 min and to 1 M in 30 min, 4 ml/min) in Tris chloride buffer (20 mM, pH 7.6). The chromatograms of the anion exchange chromatography after different incubation times are shown in Figure 3.

Analysis of the product duplex oligodeoxynucleotide 8·7 by reversed-phase HPLC-coupled electrospray ionization mass spectrometry: RP-HPLC/ESI-MS was performed as described before for the analysis of 5·4 (see example 1, 3.1). The obtained RP-HPLC/ESI mass spectrum is shown in Figure 4 and the observed molecular weights of oligodeoxynucleotides are summarized in Table 2.

Table 2

Compound	Charge	(<i>m/z</i>) _{expt}	<i>M</i> _{expt}	<i>M</i> _{calcd}
8·7	3 –	2738.4	8220.2	8215.5
8·7	4 –	2054.1	8220.4	8215.5
8·7	5 –	1642.8	8219.0	8215.5

Analysis of the product duplex oligodeoxynucleotide 8·7 by enzymatic fragmentation: Enzymatic fragmentation of 8·7 was performed as described before for 5·4 (see example 1, 3.1). The RP-HPLC analysis of the digest revealed besides dC, dC^{Me}, dA, dG, T an additional compound eluting before dC.

Example 2

1. Synthesis of a fluorescent N-adenosylaziridine derivative, compound 9 (Scheme 6).
- 1.1 8-Amino[1''-(4''-aminobutyl)]-2',3'-O-isopropylidene adenosine, compound 10.

To a solution of 8-bromo-2',3'-O-isopropylene adenosine (M. Ikehara, H. Tada, M. Kaneko, *Tetrahedron* 1968, 24, 3489-3498) (628 mg, 1.6 mmol) in dry DMSO (10 ml) under an argon atmosphere, dry triethylamine (2.26 ml, 16.3 mmol) and 1,4-diaminobutane (0.82 ml, 8.1 mmol) were added. The solution was stirred at 110°C and the reaction progress monitored by TLC. After 4 h the solvent was removed under reduced pressure. The residue was dissolved in water (50 ml) and the pH was adjusted to 5.3 with acetic acid (0.1 M). The crude product was purified by cation exchange chromatography (Dowex 50 x 4 in H⁺-form, 100 g, elution with 600 ml water and subsequently with 1000 ml 1 M potassium hydroxide). Fractions containing the product were extracted with chloroform, and the solvent was removed under reduced pressure. Yield: 639 mg (100%).

*R*_f = 0.44 (butanol/acetic acid/water 3:0.75:1.25).

¹H NMR (500 MHz, CDCl₃): δ = 1.33 (s, 3H; acetonide-H), 1.48–1.55 (m, 2H; linker-H), 1.61 (s, 3H; acetonide-H), 1.64–1.70 (m, 2H; linker-H), 2.66–2.73

(m, 2H; linker-H), 3.33–3.42 (m, 2H; linker-H), 3.77–3.91 (m, 2H; 5'-H), 4.28–4.30 (m, 1H; 4'-H), 4.99 (dd, $^3J = 2.7, 6.3$ Hz, 1H; 3'-H), 5.08 (dd, $^3J = 4.8, 6.3$ Hz, 1H; 2'-H), 5.39 (s, br., 2H; 6-NH₂), 6.15 (d, $^3J = 4.5$ Hz, 1H; 1'-H), 6.55–6.60 (m, 1H; 8-NH), 8.10 (s, 1H; 2-H).

¹³C-NMR (125.7 MHz, CDCl₃): δ = 25.30 (q; acetonide-CH₃), 25.73 (t; linker-C), 27.42 (q; acetonide-CH₃), 29.60 (t; linker-C), 40.46 (t; linker-C), 42.69 (t; linker-C), 61.17 (t; 5'-C), 80.59 (d; 3'-C), 82.19 (d; 2'-C), 84.48 (d; 4'-C), 89.21 (d; 1'-C), 114.50 (s; acetonide-C(CH₃)₂), 117.68 (s; 5-C), 149.49 (d; 2-C), 149.95 (s; 8-C), 151.68 (s; 4-C), 151.72 (s; 6-C).

ESI-MS: *m/z* (%): 394.3 (25) [M + H]⁺, 222.3 (100) [adenine + aminobutyl + H]⁺.

1.2 8-Amino[1''-(N''-dansyl)-4''-aminobutyl]-2',3'-O-isopropylidene adenosine, compound 11.

To a solution of 10 (104 mg, 0.26 mmol) in dry pyridine (7 ml) under an argon atmosphere, trimethylchlorosilane (0.07 ml, 0.53 mmol) was added slowly at 0°C, and the resulting solution was stirred at room temperature for 1 h. Subsequently, dansyl chloride (103.8 mg, 0.37 mmol, in 3 ml pyridine) was added and the solution was stirred at room temperature for 4 h. The progress of the reaction was monitored by TLC, and after complete conversion the solution was treated with water (5 ml) at 0°C. The solvent was removed under reduced pressure, and the crude product was purified by column chromatography (silica gel, 40 g, elution with methylene chloride/methanol 19:1). Yield: 50 mg (30%).

*R*_f = 0.54 (methylene chloride/methanol 9:1).

¹H-NMR (500 MHz, DMSO-*d*₆): δ = 1.29 (s, 3H; acetonide-H), 1.39–1.43 (m, 2H; linker-H), 1.47–1.50 (m, 2H; linker-H), 1.53 (s, 3H; acetonide-H), 2.78–2.82 (m, 8H; linker-H and N(CH₃)₂), 3.16–3.24 (m, 2H; linker-H), 3.50–3.58 (m, 2H; 5'-H), 4.12–4.14 (m, 1H; 4'-H), 4.94 (dd, $^3J = 2.7, 6.1$ Hz, 1H; 3'-H), 5.33 (dd, $^3J = 3.7, 6.1$ Hz, 1H; 2'-H), 5.41–5.44 (m, 1H; 5'-OH), 6.01 (d, $^3J = 3.5$ Hz, 1H; 1'-H), 6.49 (s, br., 2H; 6-NH₂), 6.85 (t, $^3J = 5.0$ Hz, 1H; 8-NH), 7.22 (d, $^3J = 7.5$ Hz, 1H; arom.-H), 7.54–7.61 (m, 2H; arom.-H), 7.87–7.90 (m, 1H; NHSO₂), 7.90 (s, 1H; 2-H), 8.08 (d, $^3J = 7.2$ Hz, 1H; arom.-H), 8.30 (d, $^3J = 8.5$ Hz, 1H; arom.-H), 8.43 (d, $^3J = 8.5$ Hz, 1H; arom.-H).

^{13}C -NMR (125.7 MHz, $\text{DMSO}-d_6$): δ = 25.42 (q; acetonide- CH_3), 26.00 (t; linker-C), 26.96 (t; linker-C), 27.33 (q; acetonide- CH_3), 41.92 (t; linker-C), 42.43 (t; linker-C), 45.21 (q; $\text{N}(\text{CH}_3)_2$), 61.40 (t; 5'-C), 81.14 (d; 3'-C), 81.50 (d; 2'-C), 85.29 (d; 4'-C), 87.85 (d; 1'-C), 113.38 (s), 115.24 (d; arom.-C), 117.24 (s), 119.29 (d; arom.-C), 123.72 (d; arom.-C), 127.92 (d; arom.-C), 128.31 (d; arom.-C), 129.26 (s), 129.48 (d; arom.-C), 136.27 (s), 148.89 (d; 2-C), 149.30 (s), 151.20 (s), 151.50 (s), 152.58 (s).

ESI-MS: m/z (%): 627.1 (100) $[\text{M} + \text{H}]^+$, 455.2 (8) [adenine + linker + dansyl + $\text{H}]^+$.

1.3 8-Amino[1''-(N''-dansyl)-4''-aminobutyl]-2',3'-O-isopropylidene-5'-O-mesyl adenosine, compound 12.

To a solution of 11 (181 mg, 0.32 mmol) and dimethylaminopyridine (40 mg, 0.32 mmol) in dry methylene chloride (20 ml) under an argon atmosphere, dry triethylamine (1.1 ml, 8.0 mmol) was added and the resulting solution was cooled to 0°C . Mesylchloride (200 μl , 2.6 mmol) was added and the solution was stirred for 30 min. The reaction was quenched with a cold, saturated sodium hydrogencarbonate solution (5 ml). The solution was extracted three times with cold chloroform (10 ml). The organic phases were combined and the solvent removed under reduced pressure. The crude product was purified by column chromatography (silica gel, 40 g, elution with methylene chloride/methanol 97:3). Yield: 96 mg (43 %).

R_f = 0.55 (methylene chloride/methanol 9:1).

^1H -NMR (500 MHz, CDCl_3): δ = 1.37 (s, 3H; acetonide-H), 1.45–1.48 (m, 2H; linker-H), 1.59–1.61 (m, 5H; linker-H and acetonide-H), 2.85 (s, 6H; $\text{N}(\text{CH}_3)_2$), 2.96 (s, 3H; SO_2CH_3), 2.98–3.02 (m, 2H; linker-H), 3.32–3.36 (m, 2H; linker-H), 4.33–4.43 (m, 3H; 5'-H and 4'-H), 5.03 (dd, 3J = 9.8, 6.1 Hz, 1H; 3'-H), 5.52 (dd, 3J = 2.5, 6.5 Hz, 1H; 2'-H), 6.04 (d, 3J = 2.5 Hz, 1H; 1'-H), 6.13 (s, br., 2H; 6- NH_2), 6.91 (t, 3J = 5.8 Hz, 1H; 8-NH), 7.13 (d, 3J = 7.3 Hz, 1H; arom.-H), 7.43 (t, 3J = 8.2 Hz, 1H; arom.-H), 7.50 (t, 3J = 7.9 Hz, 1H; arom.-H), 8.10 (s, 1H; 2-H), 8.23 (d, 3J = 7.0 Hz, 1H; arom.-H), 8.37 (d, 3J = 8.5 Hz, 1H; arom.-H), 8.51 (d, 3J = 8.6 Hz, 1H; arom.-H).

^{13}C -NMR (125.7 MHz, CDCl_3): δ = 24.62 (q; acetonide- CH_3), 25.30 (t; linker-C), 26.89 (t; linker-C), 27.04 (q; acetonide- CH_3), 37.50 (q; SO_2CH_3), 41.58 (t; linker-C), 42.70 (t; linker-C), 45.44 (q; $\text{N}(\text{CH}_3)_2$), 68.38 (t; 5'-C), 80.10 (d; 3'-C), 82.11 (d; 2'-C), 83.29 (d; 4'-C), 88.63 (d; 1'-C), 115.16 (d; arom.-C), 118.94 (d; arom.-C), 123.23 (d; arom.-C), 128.20 (d; arom.-C), 129.70 (d; arom.-C), 130.37 (d; arom.-C), 149.78 (d; 2-C), 151.84 (s), 152.41 (s).

ESI-MS: m/z (%): 705.3 (70) $[\text{M} + \text{H}]^+$, 609.7 (100) [cyclonucleoside + $\text{H}]^+$.

1.4 8-Amino[1''-(N''-dansyl)-4''-aminobutyl]-5'-O-mesyl adenosine, compound 13.

Nucleoside 12 (96.2 mg, 0.14 mmol) was dissolved in aqueous formic acid (50%, 10 ml), and the resulting solution was stirred at room temperature for 4 d. After complete conversion the solvent was removed under reduced pressure and remaining solvent was coevaporated with a mixture of water and methanol (1:1, 5 ml). The crude product was purified by column chromatography (silica gel, 15 g, elution with methylene chloride/methanol 9:1). Yield: 49.2 mg (55 %).

R_f = 0.23 (methylene chloride/methanol 9:1).

^1H -NMR (500 MHz, $\text{DMSO}-d_6$): δ = 1.36–1.42 (m, 2H; linker-H), 1.47–1.53 (m, 2H; linker-H), 2.77–2.79 (m, 2H; linker-H), 2.81 (s, 6H; $\text{N}(\text{CH}_3)_2$), 3.07 (s, 3H; SO_2CH_3), 3.17–3.20 (m, 2H; linker-H), 4.01–4.04 (m, 1H; 4'-H), 4.33–4.47 (m, 3H; 5'-H and 3'-H), 5.08 (ddd = q, 3J = 5.5 Hz, 1H; 2'-H), 5.37 (d, 3J = 5.5 Hz, 1H; OH), 5.44 (d, 3J = 5.5 Hz, 1H; OH), 5.72 (d, 3J = 5.1 Hz, 1H; 1'-H), 6.48 (s, br., 2H; 6- NH_2), 6.78 (t, 3J = 5.3 Hz, 1H; 8-NH), 7.24 (d, 3J = 7.8 Hz, 1H; arom.-H), 7.57 (t, 3J = 8.3 Hz, 1H; arom.-H), 7.61 (t, 3J = 7.8 Hz, 1H; arom.-H), 7.88 (s, 1H; 2-H), 7.95 (t, 3J = 5.7 Hz, 1H; NHSO_2), 8.08 (d, 3J = 6.9 Hz, 1H; arom.-H), 8.28 (d, 3J = 8.7 Hz, 1H; arom.-H), 8.44 (d, 3J = 8.7 Hz, 1H; arom.-H).

^{13}C -NMR (125.7 MHz, $\text{DMSO}-d_6$): δ = 27.24 (t; linker-C), 28.06 (t; linker-C), 37.91 (q; SO_2CH_3), 43.07 (t; linker-C), 43.58 (t; linker-C), 46.41 (q; $\text{N}(\text{CH}_3)_2$), 71.21 (t; 5'-C), 71.45 (d; 3'-C), 71.61 (d; 2'-C), 82.20 (d; 4'-C), 88.63 (d; 1'-C), 116.44 (d; arom.-C), 118.76 (s), 120.46 (d; arom.-C), 124.98 (d; arom.-C), 129.16 (d; arom.-C), 129.54 (d; arom.-C), 130.34 (s), 130.39 (d; arom.-C), 130.68 (s), 137.35 (s), 149.95 (d; 2-C), 150.78 (s), 152.66 (s), 153.06 (s), 153.73 (s).

ESI-MS: m/z (%): 665.6 (85) $[M + H]^+$, 687.4 (100) $[M + Na]^+$.

1.5 Synthesis of 8-Amino[1''-(N''-dansyl)-4''-aminobutyl]-5'-(1-aziridinyl)-5'-deoxy adenosine, compound 9

Nucleoside 13 (20 mg, 30 μ mol) was dissolved in dry aziridine (S. Gabriel, *Chem. Ber.* 1888, 21, 2664-2669; S. Gabriel, R. Stelzner, *Chem. Ber.* 1895, 28, 2929-2938) (1 ml) and N-ethyldiisopropylamine (350 μ l) under an argon atmosphere, and stirred at room temperature for 3 d. The reaction was monitored by analytical reversed-phase HPLC (Hypersil-ODS, 5 μ m, 120 Å, 250 x 4.6 mm, Bischoff, Leonberg, Germany). Compounds were eluted with acetonitrile (0% for 5 min, followed by a linear gradient to 35% in 30 min and to 70% in 10 min, 1 ml/min) in triethylammonium acetate buffer (0.1 M, pH = 7.0). The solvent was removed under reduced pressure after completeness of the reaction. The crude product was purified by column chromatography (silica gel, 2 g, elution with methylene chloride/methanol 9:1). Yield: 6.7 mg (36%).

R_f = 0.23 (methylene chloride/methanol 9:1).

$^1\text{H-NMR}$ (500 MHz, DMSO- d_6): δ = 1.19–1.22 (m, 2H; aziridine-H), 1.32–1.34 (m, 2H; linker-H), 1.37–1.39 (m, 2H; linker-H), 1.59–1.61 (m, 2H; aziridine-H), 1.94 (dd, 3J = 3.2 Hz, 2J = 13.5 Hz, 1H; 5'-H_a), 2.74–2.79 (m, 2H; linker-H), 2.81 (s, 6H; N(CH₃)₂), 2.91–2.95 (m, 1H; 5'-H_b), 3.07–3.16 (m, 2H; linker-H), 3.94–3.96 (m, 1H; 4'-H), 4.19–4.21 (m, 1H; 3'-H), 4.63–4.67 (m, 1H; 2'-H), 5.20 (d, 3J = 4.1 Hz, 1H; OH), 5.30 (d, 3J = 6.8 Hz, 1H; OH), 5.90 (d, 3J = 7.2 Hz, 1H; 1'-H), 6.42 (s, br., 2H; 6-NH₂), 7.23 (d, 3J = 7.2 Hz, 1H; arom.-H), 7.55–7.61 (m, 3H; arom.-H and 8-NH), 7.87 (s, 1H; 2-H), 7.95 (t, 3J = 5.6 Hz, 1H; NHSO₂), 8.08 (d, 3J = 7.2 Hz, 1H; arom.-H), 8.28 (d, 3J = 8.6 Hz, 1H; arom.-H), 8.43 (d, 3J = 8.6 Hz, 1H; arom.-H).

$^{13}\text{C-NMR}$ (125.7 MHz, DMSO- d_6): δ = 26.92 (t; aziridine-C), 27.43 (t; linker-C), 28.01 (t; linker-C), 30.02 (t; aziridine-C), 43.02 (t; linker-C), 43.65 (t; linker-C), 46.41 (q; N(CH₃)₂), 62.96 (t; 5'-C), 71.14 (d; 2'-C), 72.29 (d; 3'-C), 85.31 (d; 4'-C), 87.11 (d; 1'-C), 116.45 (d; arom.-C), 118.20 (s), 120.45 (d; arom.-C), 124.96 (d; arom.-C), 129.16 (d; arom.-C), 129.57 (d; arom.-C), 130.00 (s), 130.36 (d; arom.-C), 130.68 (s), 137.37 (s), 149.86 (d; 2-C), 151.49 (s), 152.42 (s), 152.66 (s), 153.43 (s).

ESI-MS: m/z (%): 612.7 (100) $[M + H]^+$.

2. Enzyme reaction with the N6-adenine DNA methyltransferase M·*TaqI*. (Scheme 7)

The enzyme-catalyzed reaction was carried out in a mixture (500 μ l) of cofactor free M·*TaqI* (5 nmol, 10 μ M), duplex oligodeoxynucleotide 3·4 (5 nmol, 10 μ M), compound 9 (10 nmol, 20 μ M), Tris acetate (20 mM, pH 6.0), potassium acetate (50 mM), magnesium acetate (10 mM) and Triton X-100 (0.01%) at 37°C. The progress of the reaction was monitored by anion exchange chromatography (Poros 10 HQ, 10 μ m, 4.6 x 10 mm, PerSeptive Biosystems, Germany). Compounds were eluted with aqueous potassium chloride (0.2 M for 5 min, followed by a linear gradient to 0.5 M in 5 min and to 1 M in 30 min) in Tris chloride buffer (10 mM, pH 7.0). Complete conversion to a new product (containing DNA and protein) with a retention time of 7.9 min was observed after 15 h. (No conversion of the duplex oligodeoxynucleotide 3·4 was observed in a parallel control experiment without M·*TaqI*.) For the fragmentation of the obtained protein–DNA complex the reaction solution was treated with a potassium hydroxide solution (10 M) to adjusted the pH to 8.0. Then, a solution (4 μ l) of proteinase K (31 mg/ml), Tris chloride (50 mM, pH 8.0) and calcium chloride (1 mM) was added, and the reaction mixture was incubated at 37°C for 1 h. The proteolytic fragmentation was monitored by anion exchange chromatography as described above. The fluorescent species with a retention time of 7.9 min disappeared and the new fluorescent compound 14·4 with a retention time of 29.2 min was formed (Figure 5). For further characterization the product 14·4 was isolated by reversed phase chromatography (column: Hypersil-ODS, 5 μ m, 120 Å, 250 x 4.6 mm, Bischoff, Leonberg, Germany; elution: triethylammonium acetate buffer, 0.1 M, pH 7.0 for 5 min, followed by a linear acetonitrile gradient to 35% in 30 min, 1 ml/min).

Analysis of the product duplex oligodeoxynucleotide 14·4 by enzymatic fragmentation: Purified 14·4 (0.57 OD at 260 nm) was dissolved in potassium phosphate buffer (10 mM, pH 7.0, 228 μ l) containing magnesium chloride (10 mM), DNase I (2.7 U), phosphodiesterase from *Crotalus durissus* (0.041 U), phosphodiesterase from calf spleen (0.055 U) and alkaline phosphatase (13.7 U) and incubated at 37°C for 20 h. An aliquot (100 μ l) was injected onto a reversed-phase HPLC column (Hypersil-ODS, 5 μ m,

120 Å, 250 x 4.6 mm, Bischoff, Leonberg, Germany), and the products were eluted with a gradient of acetonitrile (0–10.5% in 30 min followed by 10.5–28% in 10 min and 28–70% in 15 min, 1 ml/min) in triethylammonium acetate buffer (0.1 M, pH 7.0). Beside the deoxynucleosides dC, dA, dG, T, and dA^{Me} a new fluorescent compound eluting after 49 min was found. This new compound was isolated and detected as positively charged ion at m/z 863.1 by ESI-MS (LCQ connected to a nanoelectrospray ion source, Finnigan MAT, Germany). The observed mass is in good agreement with the calculated molecular mass (863.4) of a protonated, with 9 modified 2'-deoxyadenosine.

3. Fluorescent labeling

3.1 Fluorescent labeling of plasmid DNA using the N6-adenine DNA methyltransferase M·*TaqI*.

The enzyme-catalyzed labeling reaction was carried out in a mixture (500 µl) of cofactor free M·*TaqI* (133 nM), pUC19 DNA (28 nM, 4 recognition sites for M·*TaqI*), compound 9 (20 µM), Tris acetate (20 mM, pH 6,0), potassium acetate (50 mM), magnesium acetate (10 mM) and Triton X-100 (0,01%) at 65°C. The progress of the reaction was monitored by anion exchange chromatography (NUCLEOGEN DEAE 4000-7, 7 µm, 125 x 6,2 mm, Machery-Nagel, Düren, Germany). Compounds were eluted with aqueous potassium chloride (0.2 M for 5 min followed by a linear gradient to 1 M in 30 min) in Tris chloride buffer (10 mM, pH 7.0) containing acetonitrile (20%). The chromatograms of the anion exchange chromatography after different incubation times are shown in Figure 6 (A: UV detection at 260 nm; B: fluorescence detection). The delay between the observed UV absorption and the fluorescence is due to a spatial separation of the UV detector and the fluorescence detector. The labeling reaction yielding fluorescent pUC19 was completed after 8 h. No fluorescently labeled pUC19 was observed in a parallel control experiment without M·*TaqI* (Figure 7A and 7B).

3.2 Fluorescent labeling of plasmid DNA using the C5-cytosine DNA methyltransferase M·*HhaI*.


The enzyme-catalyzed labeling reaction was carried out in a mixture (100 µl) of M·*HhaI* (730 nM), pUC19 DNA (40 nM, 17 recognition sites for M·*HhaI*), compound 9 (20 µM), Tris chloride (10 mM, pH 6.85), sodium chloride (50 mM), EDTA (0,5 mM) and β-mercaptoethanol (2 mM) at 37°C. A parallel

control experiment was performed without *M·Hhal*. Aliquots of both incubations after 20 h reaction time were analyzed by anion exchange chromatography as described above (see example 2, 3.1). The obtained chromatograms are shown in Figure 8 (A: UV detection at 260 nm; B: fluorescence detection). No fluorescent labeling was observed in absence of *M·Hhal*.

T07220" T4944260

Claims

1. Aziridine derivative represented by formula (I)



wherein X is N or CH, Y is N or $-\text{CR}^3$, R^1 and R^3 independently from each other are H, ^3H , $-\text{NH}(\text{CH}_2)_n\text{NHR}^4$ or $-\text{NH}(\text{C}_2\text{H}_5\text{O})_n\text{C}_2\text{H}_5\text{NHR}^4$, with R^4 being selected from fluorophores, affinity tags, crosslinking agents, chromophores, proteins, peptides, amino acids which may optionally be modified, nucleotides, nucleosides, nucleic acids, carbohydrates, lipids, PEG, transfection reagents, beads and intercalating agents and n being an integer from 1-5000, and R^2 is selected from H, ^3H , $-\text{N}(\text{CH}_2)_n\text{NHR}^4$, $-\text{NH}(\text{C}_2\text{H}_5\text{O})_n\text{C}_2\text{H}_5\text{NHR}^4$ wherein R^4 and n are as defined above, $-\text{CH}_2\text{CH}(\text{COOH})(\text{NH}_2)$ or an electron-withdrawing group.

2. Aziridine derivative of claim 1, wherein X and Y are both N.
3. Aziridine derivative of claim 1, wherein only one of R^1 , R^2 and R^3 is $-\text{NH}(\text{CH}_2)_n\text{NHR}^4$ or $-\text{NH}(\text{C}_2\text{H}_5\text{O})_n\text{C}_2\text{H}_5\text{NHR}^4$, the other(s) being H.
4. Aziridine derivative of claim 1, wherein said fluorophore is selected from BODIPY, coumarin, dansyl, fluorescein, mansyl, pyrene, rhodamine, Texas red, TNS, the cyanine fluorophores Cy2, Cy3, Cy3.5, Cy5, Cy5.5 and Cy7, and derivatives thereof.
5. Aziridine derivative of claim 1, wherein said affinity tag is a peptide tag, biotin, digoxigenin or dinitrophenol.

6. Aziridine derivative of claim 5, wherein said peptide tag is his-tag or any tag with metal chelating properties which can be used in IMAC, strep-tag, flag-tag, c-myc-tag, epitopes or glutathione.
7. Aziridine derivative of claim 1, wherein said crosslinking agent is maleimide, iodacetamide, a derivative thereof or an aldehyde derivative, or a photocrosslinking agent.
8. Aziridine derivative of claim 7, wherein said photocrosslinking agent is an arylazide, a diazo compound or a benzophenone compound.
9. A complex of the compound of any one of claims 1 to 8 and a methyltransferase which normally uses S-adenoyl-L-methionine (SAM) as a cofactor.
10. The complex of claim 9, wherein said methyltransferase normally transfers the methyl group of SAM onto a nucleic acid molecule, a polypeptide, a protein, an enzyme or a small molecule.
11. The complex of claim 10, wherein said methyltransferase methylates DNA.
12. The complex of claim 11, wherein said methyltransferase is part of a restriction modification system of a bacterium.
13. The complex of claim 10, wherein said methyltransferase methylates proteins at distinct amino acids.
14. The complex of claim 12, wherein the methyltransferase is selected from the DNA methyltransferases M·*TaqI* and M·*HhaI*.
15. A kit comprising the compound of any one of claim 1 to 8.
16. The kit of claim 15 further comprising a methyltransferase as defined in any one of claims 9 to 14.
17. A kit comprising the complex of any one of claims 9 to 14.
18. A pharmaceutical composition comprising the compound of any one of claims 1 to 8 or the complex of any one of claims 9 to 14 and optionally a pharmaceutically acceptable carrier.

19. A diagnostic composition comprising the compound of any one of claims 1 to 8 or the complex of any one of claims 9 to 14.
20. Use of the compound of any one of claims 1 to 8 for modifying a target molecule.
21. The use of claim 20, wherein the modification of the target molecule is achieved by using the compound of any one of claims 1 to 8 as a cofactor of a methyltransferase which transfers the compound or part of the compound onto the target molecule.
22. The use of claim 20 or 21, wherein the target molecule is a nucleic acid molecule, a polypeptide, a synthetic polymer or a small molecule.
23. The use of claim 22, wherein the nucleic acid molecule is DNA or RNA or hybrids thereof.
24. The use of claim 22, wherein the small molecule is a lipid.
25. The use of claim 22, wherein the polypeptide is a protein or a fusion protein comprising a methylation site.
26. The use of any one of claims 21 to 25 wherein the methyltransferase is a methyltransferase as defined in any one of claims 9 to 14.
27. A method for the preparation of a modified target molecule comprising the incubation of the target molecule with the compound of any one of claims 1 to 8 in the presence of a methyltransferase which is capable of using the compound as a cofactor and under conditions which allow the transfer of the compound or of part of it onto the target molecule.
28. The method of claim 27, wherein the methyltransferase is a methyltransferase as defined in any one of claims 9 to 14.
29. The method of claim 27 or 28, wherein the target molecule is as defined in any one of claims 22 to 25.
30. Modified target molecule obtainable by the method of any of claims 27 to 29.

Fig. 1





Fig. 2

A



B




Fig. 3




Fig. 4




Fig. 5




Fig. 6



A**B**

Fig. 7





A**B**

Fig. 8

A**B**

Attorney's Docket No.: 11413-003001
 Client's Ref. No.: B 2286 US

COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled NEW COFACTORS FOR METHYLTRANSFERASES, the specification of which:

- ☐ is attached hereto.
☒ was filed on _____ as Application Serial No. 09/744,641 and was amended on _____.
☐ was described and claimed in PCT International Application No. _____ filed on _____ and as amended under PCT Article 19 on _____.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose all information I know to be material to patentability in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby claim the benefit under Title 35, United States Code, §119(e)(1) of any United States provisional application(s) listed below:

U.S. Serial No.	Filing Date	Status
None		

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose all information I know to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56(a) which became available between the filing date of the prior application and the national or PCT international filing date of this application:

U.S. Serial No.	Filing Date	Status
None		

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

Country	Application No.	Filing Date	Priority Claimed
EP	98 11 4201.1	29 July 1998	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

PCT/EP/01/00000

I hereby appoint the following attorneys and/or agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

20 Richard J. Anderson, Reg. No. 36,732; Gregory P. Einhorn, Reg. No. 38,440; Mark S. Ellinger, Reg. No. 34,812; J. Eldora L. Ellison, Reg. No. 39,967; Peter Fasse, Reg. No. 32,983; J. Patrick Finn, III, Reg. No. 44,109; Janis K. Fraser, Reg. No. 34,819; John W. Freeman, Reg. No. 29,066; Diane L. Gardner, Reg. No. 36,518; Scott Harris, Reg. No. 32,030; John F. Hayden, Reg. No. 37,640; George Heibel, 42,648; Donald C. Kordich, Reg. No. 38,213; Ronald C. Lundquist, Reg. No. 37,875; Anita L. Meiklejohn, Reg. No. 35,283; Mike P. Reed, Reg. No. 45,647; Reginald Suyat, Reg. No. 28,172; Y. Rocky Tsao, Reg. No. 34,054; Hans R. Troesch, Reg. No. 36,950; Dorothy P. Whelan, Reg. No. 33,814, of FISH & RICHARDSON P.C.

Address all telephone calls to GREGORY P. EINHORN at telephone number (858) 678-5070.

Address all correspondence to GREGORY P. EINHORN at:

FISH & RICHARDSON P.C.
4350 La Jolla Village Drive, Suite 500
San Diego, CA 92122

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

Full Name of
Inventor:

1-20 MARC PIGNOT

Inventor's
Signature:

Mac Pignot

Date:

e: 07/13/01

Residence
Address:

Freiherr-vom-Stein Str. 4, D-65812 Bad Soden Germany

Citizenship:

Germany

Post Office

Freiherr-vom-Stein Str. 4, D-65812 Bad Soden Germany

Address:

Full Name of
Inventor:

20 ELMAR WEINHOLD

Inventor's
Signature:

Elmar Weinhold

Date:

e: 07/13/01

Residence
Address:

Jakob-Str. 112, D-52064 Aachen Germany

Citizenship:


Germany

Post Office

Jakob-Str. 112, D-52064 Aachen Germany

Address:

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

*There are only 8 sheet of drawing
fig 1 to 8.*

☐ **Scanned copy is best available.** *There is a line
on Declaration pages.*